- Home
- SPOK vs ATAI Comparison
SPOK vs ATAI Comparison
Compare SPOK & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- ATAI
- Stock Information
- Founded
- SPOK 2004
- ATAI 2018
- Country
- SPOK United States
- ATAI Germany
- Employees
- SPOK 419
- ATAI N/A
- Industry
- SPOK Telecommunications Equipment
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- SPOK Telecommunications
- ATAI Health Care
- Exchange
- SPOK Nasdaq
- ATAI Nasdaq
- Market Cap
- SPOK 379.1M
- ATAI 444.7M
- IPO Year
- SPOK 1992
- ATAI 2021
- Fundamental
- Price
- SPOK $18.41
- ATAI $3.88
- Analyst Decision
- SPOK Hold
- ATAI Strong Buy
- Analyst Count
- SPOK 1
- ATAI 3
- Target Price
- SPOK $15.00
- ATAI $13.33
- AVG Volume (30 Days)
- SPOK 150.4K
- ATAI 7.1M
- Earning Date
- SPOK 07-30-2025
- ATAI 08-14-2025
- Dividend Yield
- SPOK 6.79%
- ATAI N/A
- EPS Growth
- SPOK 10.71
- ATAI N/A
- EPS
- SPOK 0.83
- ATAI N/A
- Revenue
- SPOK $140,742,000.00
- ATAI $2,309,000.00
- Revenue This Year
- SPOK $2.26
- ATAI $423.05
- Revenue Next Year
- SPOK $2.54
- ATAI N/A
- P/E Ratio
- SPOK $22.17
- ATAI N/A
- Revenue Growth
- SPOK 1.79
- ATAI 510.85
- 52 Week Low
- SPOK $13.55
- ATAI $1.03
- 52 Week High
- SPOK $19.31
- ATAI $4.40
- Technical
- Relative Strength Index (RSI)
- SPOK 57.50
- ATAI 57.64
- Support Level
- SPOK $17.93
- ATAI $3.87
- Resistance Level
- SPOK $18.79
- ATAI $4.27
- Average True Range (ATR)
- SPOK 0.51
- ATAI 0.34
- MACD
- SPOK 0.02
- ATAI -0.05
- Stochastic Oscillator
- SPOK 62.03
- ATAI 53.98
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.